NVGN Key Stats
- Novogen (NVGN) Announces Three Board Appointments, Names One Advisor Street Insider 03/04 16:30 ET
- Novogen appoints David Gryska as strategic advisor Yahoo 03/04 06:10 ET
- Novogen Appoints New Board Members and Strategic Advisor to Support Transition to Clinical Development and Growing International Presence PR Newswire] - NASDAQ:NVGN 03/04 06:00 ET
- Novogen Announces Key Appointments to Drive Development of Anti-Tropomyosin Drug Platform Other 02/03 12:30 ET
- Novogen to Host Corporate Update and Webcast Other 01/30 18:54 ET
- Novogen to Present at Biotech Showcase™ 2014 PR Newswire 01/08 07:30 ET
- Novogen Announces Establishment of Global Collaboration to Drive The Development of Drugs to Treat Brain Cancer PR Newswire 12/20 08:00 ET
- Novogen Files Suite of Patents for Anti-Tropomyosin Drug Technology PR Newswire 11/26 08:42 ET
- Novogen (NVGN) Unit Reports Strong Trilexium Data on Ovarian Cancer Street Insider 11/25 06:15 ET
- Wal-Mart’s Soft Quarter, Rio Tinto’s Arizona Mine Project, and 3 More Hot Stocks Wall St. Cheat Sheet 11/14 11:47 ET
NVGN Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Novogen is down 24.20% over the last year vs S&P 500 Total Return up 24.21%, AstraZeneca up 53.03%, and Bell Rose Capital down 0.10%.
Balance Sheet View Statement
Pro Ratings for NVGN
Pro Strategies Featuring NVGN
Did Novogen make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.
- Sector: Healthcare
- Industry: Drug Manufacturers - Major
- Headquarters Country: Australia
- Headquarters State/Province: N/A
- Incorporation Country: Australia
- Incorporation State/Province: N/A
Novogen Ltd., is engaged in pharmaceutical drug development. It develops single drug capable of killing both the dominant differentiated cells in a cancer as well as the undifferentiated cancer stem cells at a therapeutic dose.